MedTrace Logo

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

NCT00673218 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-07-06

No results posted yet for this study

Summary

If you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. We will perform experiments on your blood cells.

Conditions

  • Allergy

Interventions

DRUG

Placebo

Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.

DRUG

Xolair

150 to 375 mg is administered SC every 2 or 4 weeks

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Robert G Townley, MD · Creighton University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673218 on ClinicalTrials.gov